Victory Capital Management Inc. purchased a new stake in OmniAb, Inc. (NASDAQ:OABI – Free Report) in the second quarter, HoldingsChannel reports. The fund purchased 10,183 shares of the company’s stock, valued at approximately $51,000.
Other hedge funds have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new stake in OmniAb in the 2nd quarter valued at $38,000. Stephens Inc. AR bought a new position in shares of OmniAb during the 1st quarter worth about $32,000. Bailard Inc. bought a new position in shares of OmniAb during the 2nd quarter worth about $50,000. Stifel Financial Corp bought a new position in shares of OmniAb during the 1st quarter worth about $37,000. Finally, Ameritas Advisory Services LLC bought a new position in shares of OmniAb during the 2nd quarter worth about $52,000. 58.73% of the stock is owned by institutional investors.
OmniAb Stock Down 3.0 %
Shares of OmniAb stock opened at $4.56 on Tuesday. The stock has a market capitalization of $529.73 million, a P/E ratio of -19.83 and a beta of -0.43. The company has a 50-day simple moving average of $5.08 and a 200 day simple moving average of $4.80. OmniAb, Inc. has a 12-month low of $1.91 and a 12-month high of $5.97.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of OmniAb in a report on Friday, August 11th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, OmniAb presently has a consensus rating of “Buy” and a consensus price target of $10.00.
Insider Buying and Selling
In other news, CEO Matthew W. Foehr bought 45,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was acquired at an average price of $5.48 per share, for a total transaction of $246,600.00. Following the transaction, the chief executive officer now directly owns 2,332,919 shares of the company’s stock, valued at approximately $12,784,396.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.00% of the stock is currently owned by corporate insiders.
OmniAb, Inc, a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
- Five stocks we like better than OmniAb
- How to Read Stock Charts for Beginners
- These 5 small-cap impact stocks are making social change
- Market Cap Calculator: How to Calculate Market Cap
- Alphabet slays its earnings but falls on its sword with cloud
- What is Short Interest? How to Use It
- There’s nothing artificial about NVIDIA’s relationship with AI
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.